Using a med-tech strategy may help stem concern about CAR T-cell technology’s complicated distribution and anticipated high prices, said Novartis exec.
Five things for pharma marketers to know, Thursday, June 4
FDA panel votes in favor of Vertex’s combination cystic fibrosis drug; MannKind blames marketing on slow Afrezza sales; Orexigen draws ire after Contrave study terminated
Five things for pharma marketers to know: Thursday, March 26
Regeneron’s Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk
Five things for pharma marketers to know: Friday, February 20
President Barack Obama’s recently unveiled Precision Medicine Initiative hopes to develop a new model of patient-driven research with the promise of accelerating biomedical discoveries and provide clinicians with new tools, knowledge, and therapies.
Five things for pharma marketers to know: Wednesday, January 21
President Barack Obama says personalized medicines need financial support in SOTU Address; Salix explores M&A options; lobbying groups PhRMA and BIO say generic painkillers without abuse-deterrent features should be pulled from shelves.
Five things for pharma marketers to know: Monday, December 22